Zacks Investment Research upgraded shares of Pharming Group (NASDAQ:PHGUF) from a hold rating to a buy rating in a research note published on Wednesday morning. Zacks Investment Research currently has $0.25 target price on the stock.
According to Zacks, “Pharming Group NV develops innovative therapeutics for the treatment of genetic disorders, specialty products for surgical indications and nutritional products. The advanced technologies of the Company include innovative and validated platforms for the production of protein therapeutics, technology and processes for the purification and formulation of its products. Its primary product Ruconest (R) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with hereditary angioedema in the European Union countries, Norway, Iceland and Liechtenstein. Pharming Group NV is headquartered in Leiden, the Netherlands. “
Pharming Group (NASDAQ:PHGUF) opened at 0.25 on Wednesday. The stock’s 50 day moving average price is $0.00 and its 200-day moving average price is $0.00. The company’s market capitalization is $103.15 million. Pharming Group has a 52 week low of $0.17 and a 52 week high of $0.35.
About Pharming Group
Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies.